URGNUroGen Pharma Ltd.

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.

Why UroGen Pharma Stock Is Back in Focus After Q2 2026 Earnings UroGen Pharma (URGN) is back on investors radar after reporting second quarter 2026 results on 5 August, highlighted by higher reported sales and a smaller net loss for both the quarter and first half. The company reported Q2 sales of US$72.46 million with a net loss of US$14.35 million, and first half sales of US$123.42 million with a net loss of US$37.93 million, which may be reshaping sentiment around the stock. See our latest...

UroGen Pharma Ltd. reported past second-quarter 2026 results showing sales of US$72.46 million versus US$24.22 million a year earlier, with net loss narrowing to US$14.35 million from US$49.94 million and basic loss per share from continuing operations improving to US$0.28 from US$1.05. Over the first half of 2026, sales almost tripled to US$123.42 million while the net loss roughly halved to US$37.93 million, suggesting meaningful operating leverage as revenue scales. Next, we’ll examine...

UroGen Pharma Ltd (URGN) reports strong Cysview adoption and pipeline progress, while raising full-year operating expense guidance to support commercial expansion.

Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand.

UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum. URGN maintains a 100% “Buy” technical opinion from Barchart. The company’s revenue is projected to more than double this year and grow by 56% next year. Earnings are estimated to rise by 75% and...